Claims for Patent: 6,270,757

✉ Email this page to a colleague

Summary for Patent: 6,270,757

Title:	Formulations for IL-11
Abstract:	The present invention provides novel formulations comprising IL-11 and glycine. Also provided are compositions, both liquid and lyophilized, comprising IL-11 and glycine and optionally, a buffering agent such as histidine and phosphate.
Inventor(s):	Warne; Nicholas W. (Methuen, MA)
Assignee:	Genetics Institute, Inc. (Cambridge, MA)
Application Number:	08/230,982
Patent Claims:	1. A composition comprising IL-11 and glycine. 2. The composition of claim 1, where the amount of said glycine ranges from 50 to 600 mM. 3. The composition of claim 1, where the amount of said glycine is about 300 mM. 4. The composition of claim 1, where the amount of said glycine is about 150 mM. 5. The composition of claim 1, where the amount of said IL-11 is about 0.1 to 20 mg/mL. 6. The composition of claim 1, where the amount of said IL-11 is about 5.0 mg/mL. 7. The composition of claim 1, where the amount of said IL-11 is about 5.0 mg/mL and said glycine is about 300 mM. 8. A composition comprising IL-11, glycine, and a buffering agent. 9. The composition of claim 8, where said buffering agent is a member selected from the group consisting of histidine and phosphate. 10. The composition of claim 9, where said buffering agent is sodium phosphate. 11. The composition of claim 9, where the amount of said phosphate ranges from about 5 mM to 20 mM. 12. The composition of claim 10, where the amount of said phosphate is about 10 mM. 13. The composition of claim 9, where the amount of said histidine ranges from about 5 mM to 40 mM. 14. The composition of claim 11, where the amount of said histidine is about 20 mM. 15. A composition comprising about 5.0 mg/mL IL-11, 300 mM glycine, and 10 mM sodium phosphate. 16. A composition comprising about 5.0 mg/mL IL-11, 300 mM glycine, and 20 mM histidine. 17. A composition comprising des-Pro-IL-11 and glycine. 18. The composition of claim 17 where the amount of said des-Pro-IL-11 is about 0.1 to 20 mg/mL. 19. The composition of claim 17 where the amount of said glycine is about 50 to 600 mM. 20. A composition comprising about 5.0 mg/mL des-Pro-IL-11 and 300 mM glycine.

Details for Patent 6,270,757

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694	November 25, 1997	⤷ Sign Up	2039-03-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 6,270,757

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Austria	E210995	⤷ Sign Up
Australia	1934495	⤷ Sign Up
Australia	684620	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.